JP2017536825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536825A5 JP2017536825A5 JP2017527874A JP2017527874A JP2017536825A5 JP 2017536825 A5 JP2017536825 A5 JP 2017536825A5 JP 2017527874 A JP2017527874 A JP 2017527874A JP 2017527874 A JP2017527874 A JP 2017527874A JP 2017536825 A5 JP2017536825 A5 JP 2017536825A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 103
- 229920001184 polypeptide Polymers 0.000 claims 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 102000004196 processed proteins & peptides Human genes 0.000 claims 41
- 108091008874 T cell receptors Proteins 0.000 claims 18
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 9
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 239000013604 expression vector Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 238000003259 recombinant expression Methods 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021063092A JP7297807B2 (ja) | 2014-11-26 | 2021-04-01 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084654P | 2014-11-26 | 2014-11-26 | |
| US62/084,654 | 2014-11-26 | ||
| US201562171321P | 2015-06-05 | 2015-06-05 | |
| US62/171,321 | 2015-06-05 | ||
| PCT/US2015/062269 WO2016085904A1 (en) | 2014-11-26 | 2015-11-24 | Anti-mutated kras t cell receptors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021063092A Division JP7297807B2 (ja) | 2014-11-26 | 2021-04-01 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536825A JP2017536825A (ja) | 2017-12-14 |
| JP2017536825A5 true JP2017536825A5 (enExample) | 2019-01-10 |
| JP6863893B2 JP6863893B2 (ja) | 2021-04-21 |
Family
ID=54838442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527874A Active JP6863893B2 (ja) | 2014-11-26 | 2015-11-24 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
| JP2021063092A Active JP7297807B2 (ja) | 2014-11-26 | 2021-04-01 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021063092A Active JP7297807B2 (ja) | 2014-11-26 | 2021-04-01 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11207394B2 (enExample) |
| EP (3) | EP3223850B1 (enExample) |
| JP (2) | JP6863893B2 (enExample) |
| KR (1) | KR102622784B1 (enExample) |
| CN (3) | CN113956349B (enExample) |
| AU (3) | AU2015353720B2 (enExample) |
| ES (2) | ES2784261T3 (enExample) |
| HU (1) | HUE065689T2 (enExample) |
| IL (1) | IL252258B (enExample) |
| MX (1) | MX384919B (enExample) |
| PL (1) | PL3223850T3 (enExample) |
| PT (1) | PT3223850T (enExample) |
| SA (1) | SA517381608B1 (enExample) |
| SG (2) | SG10201913978RA (enExample) |
| SI (1) | SI3223850T1 (enExample) |
| WO (1) | WO2016085904A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2784261T3 (es) * | 2014-11-26 | 2020-09-23 | Us Health | Receptores de células T anti-KRAS mutado |
| ES2879287T3 (es) | 2015-09-15 | 2021-11-22 | Us Health | Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8 |
| EP4159751A1 (en) * | 2016-08-02 | 2023-04-05 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-kras-g12d t cell receptors |
| WO2018069871A2 (en) * | 2016-10-13 | 2018-04-19 | Sorrento Therapeutics, Inc. | Anti-kras binding proteins |
| KR102760578B1 (ko) | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| CN108395479B (zh) * | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| TW201907937A (zh) | 2017-05-08 | 2019-03-01 | 美商葛利史東腫瘤科技公司 | 阿爾法病毒新抗原載體 |
| WO2018208553A1 (en) * | 2017-05-12 | 2018-11-15 | Augusta University Research Institute, Inc. | Human alpha fetoprotein-specific t cell receptors and uses thereof |
| AU2018269370B2 (en) * | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| MX2020003117A (es) * | 2017-09-20 | 2020-08-20 | Us Health | Receptores de celulas t restringidas a hla de clase ii contra ras mutado. |
| CN111344394A (zh) * | 2017-09-29 | 2020-06-26 | 美国卫生和人力服务部 | 分离对p53癌症-特异性突变具有抗原特异性的t细胞的方法 |
| CA3077595A1 (en) | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| US11466071B2 (en) * | 2017-12-04 | 2022-10-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class I-restricted t cell receptors against mutated RAS |
| CN110016074B (zh) * | 2018-01-08 | 2021-03-30 | 中国科学院广州生物医药与健康研究院 | Mage-a3人源化t细胞受体 |
| WO2019246286A1 (en) * | 2018-06-19 | 2019-12-26 | Neon Therapeutics, Inc. | Neoantigens and uses thereof |
| WO2020037239A1 (en) | 2018-08-16 | 2020-02-20 | Neon Therapeutics, Inc. | T cell receptor constructs and uses thereof |
| AU2020211922B2 (en) * | 2019-01-22 | 2025-05-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA class II-restricted T cell receptors against RAS with G12R mutation |
| CA3127673A1 (en) | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| GB2596461B (en) * | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| WO2020210202A1 (en) * | 2019-04-11 | 2020-10-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer |
| BR112021023794A2 (pt) * | 2019-05-27 | 2022-01-04 | Provincial Health Services Authority | Agente de direcionamento de antígeno, molécula de ácido nucleico isolada, composição farmacêutica, célula citotóxica, e, métodos para produzir uma célula citotóxica, para realizar uma terapia celular adotiva, para realizar uma imunoterapia e para detectar câncer em um sujeito mamífero |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| US12577278B2 (en) * | 2019-06-07 | 2026-03-17 | Emory University | KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| EP3997131A4 (en) | 2019-07-12 | 2023-08-02 | The Regents of the University of California | Chemically controlled monoclonal antibody target engagement |
| CN112646024B (zh) * | 2019-10-10 | 2023-03-24 | 香雪生命科学技术（广东）有限公司 | 一种识别kras突变的t细胞受体及其编码序列 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| WO2021087840A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
| JP2023502625A (ja) * | 2019-11-15 | 2023-01-25 | グリットストーン バイオ インコーポレイテッド | 共有新抗原を標的にする抗原結合タンパク質 |
| CU20220044A7 (es) * | 2020-02-12 | 2023-06-13 | Us Health | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d |
| BR112022015897A2 (pt) * | 2020-02-14 | 2022-10-18 | Us Health | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN113684258B (zh) * | 2020-05-18 | 2024-08-20 | 上海赛比曼生物科技有限公司 | 用于检测鼠源tcr转基因拷贝数的试剂盒及方法 |
| WO2021242961A1 (en) * | 2020-05-27 | 2021-12-02 | Vanderbilt University | Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor |
| CA3185483A1 (en) * | 2020-07-16 | 2022-01-20 | Noam LEVIN | Hla class ii-restricted drb t cell receptors against ras with g12v mutation |
| EP4192496A4 (en) | 2020-08-06 | 2025-01-01 | Gritstone bio, Inc. | MULTIEPITOP VACCINE CASSETTES |
| CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
| WO2022072760A1 (en) * | 2020-10-02 | 2022-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| AU2021389909A1 (en) * | 2020-11-24 | 2023-06-22 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| IL305393A (en) | 2021-02-25 | 2023-10-01 | Alaunos Therapeutics Inc | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| CA3212382A1 (en) * | 2021-03-19 | 2022-09-22 | Ronald D. Seidel Iii | T-cell modulatory polypeptides and methods of use thereof |
| CN116063511B (zh) * | 2021-09-30 | 2023-10-03 | 北京可瑞生物科技有限公司 | 抗原结合蛋白及其应用 |
| KR102753583B1 (ko) * | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| KR102818249B1 (ko) * | 2021-11-11 | 2025-06-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
| EP4466283A1 (en) | 2022-01-21 | 2024-11-27 | T-Knife GmbH | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN114591443A (zh) * | 2022-03-07 | 2022-06-07 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种基于scTv的嵌合受体CSR及其应用 |
| CN114835800B (zh) * | 2022-05-27 | 2023-10-13 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN114920824B (zh) * | 2022-05-27 | 2023-12-05 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| WO2024055003A1 (en) * | 2022-09-08 | 2024-03-14 | The Regents Of The University Of California | Binding agent recognition of drug-peptide conjugates |
| WO2024147556A1 (ko) * | 2023-01-05 | 2024-07-11 | 의료법인 명지의료재단 | K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물 |
| IL322077A (en) * | 2023-01-13 | 2025-09-01 | Corregene Biotechnology Co Ltd | Antigen-binding protein and its use |
| CN118812698A (zh) * | 2023-04-19 | 2024-10-22 | 香雪生命科学技术（广东）有限公司 | 一种识别kras突变的高亲和力t细胞受体及其应用 |
| CN118852452A (zh) * | 2023-04-28 | 2024-10-29 | 北京鼎成肽源生物技术有限公司 | 靶向kras g12突变的tcr分子和细胞及其应用 |
| CN118909132A (zh) * | 2023-05-06 | 2024-11-08 | 北京鼎成肽源生物技术有限公司 | 靶向kras g12v突变的tcr分子和细胞及其应用 |
| WO2025006196A1 (en) | 2023-06-28 | 2025-01-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors targeting ras with g12d, g12r, or g12v mutation |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| CN117143823B (zh) * | 2023-09-11 | 2024-07-16 | 皖南医学院第一附属医院（皖南医学院弋矶山医院） | 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 |
| IL327158A (en) * | 2023-09-15 | 2026-05-01 | Funda??O D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud | T-type receptor against mKRAS7-16 G12V and G12C |
| WO2025056656A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V |
| WO2025189363A1 (zh) * | 2024-03-12 | 2025-09-18 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709002B1 (en) * | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| DK1910521T3 (da) * | 2005-08-05 | 2011-02-07 | Helmholtz Zentrum Muenchen | Generering af allo-begrænsede, antigenspecifikke T-celler |
| AU2007248019B2 (en) * | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| AU2008206442B2 (en) * | 2007-01-12 | 2012-10-18 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | gp100-specific T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| WO2011034906A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| GB2508414A (en) * | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| CN104131034B (zh) * | 2014-06-19 | 2017-04-05 | 中山大学 | 一种嵌合载体及其制备方法和应用 |
| ES2784261T3 (es) * | 2014-11-26 | 2020-09-23 | Us Health | Receptores de células T anti-KRAS mutado |
| CN105802909B (zh) * | 2014-12-31 | 2021-01-01 | 中国医学科学院基础医学研究所 | 具有her2特异性tcr的t细胞制备物及其用途 |
| CN108395479B (zh) * | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| CN113621070A (zh) * | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
-
2015
- 2015-11-24 ES ES15807756T patent/ES2784261T3/es active Active
- 2015-11-24 CN CN202111263859.8A patent/CN113956349B/zh active Active
- 2015-11-24 SG SG10201913978RA patent/SG10201913978RA/en unknown
- 2015-11-24 MX MX2017006865A patent/MX384919B/es unknown
- 2015-11-24 WO PCT/US2015/062269 patent/WO2016085904A1/en not_active Ceased
- 2015-11-24 SI SI201531151T patent/SI3223850T1/sl unknown
- 2015-11-24 ES ES20150279T patent/ES2965689T3/es active Active
- 2015-11-24 KR KR1020177017289A patent/KR102622784B1/ko active Active
- 2015-11-24 CN CN201580070673.7A patent/CN107223134B/zh active Active
- 2015-11-24 SG SG11201704155UA patent/SG11201704155UA/en unknown
- 2015-11-24 US US15/528,813 patent/US11207394B2/en active Active
- 2015-11-24 JP JP2017527874A patent/JP6863893B2/ja active Active
- 2015-11-24 EP EP15807756.0A patent/EP3223850B1/en active Active
- 2015-11-24 EP EP20150279.6A patent/EP3666288B1/en active Active
- 2015-11-24 EP EP23198524.3A patent/EP4286407B1/en active Active
- 2015-11-24 AU AU2015353720A patent/AU2015353720B2/en active Active
- 2015-11-24 PT PT158077560T patent/PT3223850T/pt unknown
- 2015-11-24 HU HUE20150279A patent/HUE065689T2/hu unknown
- 2015-11-24 CN CN202411133523.3A patent/CN118994363A/zh active Pending
- 2015-11-24 PL PL15807756T patent/PL3223850T3/pl unknown
-
2017
- 2017-05-14 IL IL252258A patent/IL252258B/en unknown
- 2017-05-25 SA SA517381608A patent/SA517381608B1/ar unknown
-
2020
- 2020-05-26 AU AU2020203465A patent/AU2020203465B2/en active Active
-
2021
- 2021-04-01 JP JP2021063092A patent/JP7297807B2/ja active Active
- 2021-11-24 US US17/535,318 patent/US12312391B2/en active Active
-
2023
- 2023-02-07 AU AU2023200614A patent/AU2023200614B2/en active Active
-
2025
- 2025-04-22 US US19/185,602 patent/US20250263462A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023159112A5 (enExample) | ||
| JP2018535647A5 (enExample) | ||
| JP2015525208A5 (enExample) | ||
| FI3688027T3 (fi) | Mutatoidun p53:n tunnistavia t-solureseptoreita | |
| JP2020511936A5 (enExample) | ||
| JP2019512242A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2015517982A5 (enExample) | ||
| JP2018526323A5 (enExample) | ||
| JP2018502572A5 (enExample) | ||
| JP2016503295A5 (enExample) | ||
| JP2015535816A5 (enExample) | ||
| CN114560930B (zh) | 抗新型冠状病毒的广谱中和抗体及其应用 | |
| JP2012143232A5 (enExample) | ||
| CN105399827B (zh) | Wasabi蛋白纳米抗体及其编码序列与应用 | |
| JP2012526542A5 (enExample) | ||
| JP2016516400A5 (enExample) | ||
| IL273254B1 (en) | HLA type II-restricted T cell receptors against RAS | |
| FI3390451T3 (fi) | Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan | |
| JP2018504610A5 (enExample) | ||
| WO2024114830A1 (zh) | 一种针对新冠病毒rbd的广谱单克隆抗体、其制备方法及应用 | |
| CN112094348A (zh) | 抗人Tim3抗体或其功能性片段及其应用 | |
| JP2017536821A5 (enExample) | ||
| CN106065031A (zh) | 基于杂交瘤技术和高通量测序的抗体发现方法 | |
| CN106008708A (zh) | 一种人乙型肝炎病毒x蛋白的单克隆抗体及用途 |